

United States Senate

WASHINGTON, DC 20510 January 24, 2023

Murray S. Kessler President and Chief Executive Officer Perrigo 515 Eastern Avenue Allegan, M.I., 49010

Mr. Kessler,

I write to inquire regarding continuing reports that Georgia's parents and guardians are having a hard time finding children's over-the-counter pain and fever-reducing medications amidst this winter's spike in viral infections.

It is extremely scary for a parent to hold a sick child, unable to provide the medicine that child needs to feel better or lower a fever.

Since earlier this fall, doctors have warned about a "tripledemic" with RSV, flu, and COVID-19, together impacting children and infants this winter. As early as October 2022, HHS Assistant Secretary for Preparedness and Response Dawn O'Connell and CDC Director Rochelle Walensky cautioned the public about these risks.

The American Academy of Pediatrics has stated that most children with RSV, flu, and other respiratory illnesses can be treated and managed at home. However, this is difficult for families when recommended medicines like children's over-the-counter pain and fever-reducing medications are not available at local retailers.

As Georgia's parents and guardians continue to face difficulties accessing these medicines, I ask you to provide answers to the below questions in writing within two weeks:

- 1. What is causing the lack of children and infant medicine on the shelves at local retailers?
- 2. Is there a shortage of medicine due to a slowdown in production?
- 3. Are there any supply chain challenges or issues sourcing ingredients?
- 4. Did Perrigo increase production and distribution after warnings from U.S. public health authorities in late Fall 2022?
- 5. How is Perrigo responding to the lack of supply on the shelves of local retailers and how will they help ease concerns from worried parents and guardians?

I look forward to your response.

Sincerely,

Jon Ossoff

United States Senator

COMMITTEE ON BANKING, HOUSING, AND URBAN AFFAIRS

COMMITTEE ON THE JUDICIARY

COMMITTEE ON HOMELAND SECURITY AND GOVERNMENTAL AFFAIRS



United States Senate

WASHINGTON, DC 20510 January 24, 2023

Joaquin Duato Chief Executive Officer Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, N.J. 08933

Mr. Duato,

I write to inquire regarding continuing reports that Georgia's parents and guardians are having a hard time finding children's Tylenol and Motrin amidst this winter's spike in viral infections.

It is extremely scary for a parent to hold a sick child, unable to provide the medicine that child needs to feel better or lower a fever.

Since earlier this fall, doctors have warned about a "tripledemic" with RSV, flu, and COVID-19, together impacting children and infants this winter. As early as October 2022, HHS Assistant Secretary for Preparedness and Response Dawn O'Connell and CDC Director Rochelle Walensky cautioned the public about these risks.

The American Academy of Pediatrics has stated that most children with RSV, flu, and other respiratory illnesses can be treated and managed at home. However, this is difficult for families when recommended medicines like children's Tylenol and Motrin are not available at local retailers.

As Georgia's parents and guardians continue to face difficulties accessing these medicines, I ask you to provide answers to the below questions in writing within two weeks:

- 1. What is causing the lack of children and infant medicine on the shelves at local retailers?
- 2. Is there a shortage of medicine due to a slowdown in production?
- 3. Are there any supply chain challenges or issues sourcing ingredients?
- 4. Did Johnson & Johnson increase production and distribution after warnings from U.S. public health authorities in late Fall 2022?
- 5. How is Johnson & Johnson responding to the lack of supply on the shelves of local retailers and how will they help ease concerns from worried parents and guardians?

I look forward to your response.

Sincerely,

Jon Ossoff

United States Senator

COMMITTEE ON BANKING, HOUSING, AND URBAN AFFAIRS

COMMITTEE ON THE JUDICIARY

COMMITTEE ON HOMELAND SECURITY AND GOVERNMENTAL AFFAIRS



United States Senate

WASHINGTON, DC 20510 January 24, 2023

Emma Walmsley Chief Executive Officer GlaxoSmithKline 2929 Walnut Street, Ste. 1700 Philadelphia, P.A. 19104

Dame Walmsley,

I write to inquire regarding continuing reports that Georgia's parents and guardians are having a hard time finding children's Advil amidst this winter's spike in viral infections.

It is extremely scary for a parent to hold a sick child, unable to provide the medicine that child needs to feel better or lower a fever.

Since earlier this fall, doctors have warned about a "tripledemic" with RSV, flu, and COVID-19, together impacting children and infants this winter. As early as October 2022, HHS Assistant Secretary for Preparedness and Response Dawn O'Connell and CDC Director Rochelle Walensky cautioned the public about these risks.

The American Academy of Pediatrics has stated that most children with RSV, flu, and other respiratory illnesses can be treated and managed at home. However, this is difficult for families when recommended medicines like children's Advil are not available at local retailers.

As Georgia's parents and guardians continue to face difficulties accessing these medicines, I ask you to provide answers to the below questions in writing within two weeks:

- 1. What is causing the lack of children and infant medicine on the shelves at local retailers?
- 2. Is there a shortage of medicine due to a slowdown in production?
- 3. Are there any supply chain challenges or issues sourcing ingredients?
- 4. Did GSK increase production and distribution after warnings from U.S. public health authorities in late Fall 2022?
- 5. How is GSK responding to the lack of supply on the shelves of local retailers and how will they help ease concerns from worried parents and guardians?

I look forward to your response.

Sincerely,

Jon Ossoff

United States Senator

COMMITTEE ON BANKING, HOUSING, AND URBAN AFFAIRS

COMMITTEE ON THE JUDICIARY

COMMITTEE ON HOMELAND SECURITY AND GOVERNMENTAL AFFAIRS